<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01654276</url>
  </required_header>
  <id_info>
    <org_study_id>MSA-FEB-137</org_study_id>
    <nct_id>NCT01654276</nct_id>
  </id_info>
  <brief_title>Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome</brief_title>
  <official_title>Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate whether the medication, febuxostat, can improve the
      degree of insulin resistance and other features of the metabolic syndrome (high blood
      pressure, elevated insulin levels, excess body fat around the waist, and/or high cholesterol)
      by lowering uric acid levels in the blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The metabolic syndrome (MS) is characterized by a constellation of metabolic features
      including dyslipidemia, hyperglycemia, hypertension, obesity, and insulin resistance. This
      cluster of features is strongly associated with type 2 diabetes, atherosclerotic
      cardiovascular disease, and increased cardiovascular and all-cause mortality. Hyperuricemia
      (elevated serum uric acid) is associated with insulin resistance and features of the MS in
      cross-sectional epidemiological studies. However, it remains unclear whether this association
      is causal or simply coincidental. If hyperuricemia CAUSES insulin resistance, then lowering
      serum uric acid by pharmacological means may result in improved insulin sensitivity and
      reversal of features of the metabolic syndrome. In some recent small studies, lowering serum
      uric acid with allopurinol was associated with improvement in some of the features and/or
      complications of the MS: Allopurinol use resulted in reduction in blood pressure in
      adolescents and improvement in exercise capacity in patients with chronic stable angina. A
      low urine pH is strongly associated with insulin resistance, and individual features of the
      metabolic syndrome. Similarly, a low fractional excretion of uric acid is also associated
      with metabolic syndrome feature. We therefore would like to examine the effect on febuxostat
      on these two parameters which have been linked with the metabolic syndrome.

      The goal of this study is to evaluate whether pharmacological lowering of serum uric acid
      with the medication febuxostat is associated with improvement in the degree of insulin
      resistance and various features of the metabolic syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Uric Acid</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulatory Systolic Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Systolic BP by ambulatory blood pressure monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulatory Diastolic Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Diastolic BP by ambulatory blood pressure monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Glucose</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Insulin</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity Measured by HOMA (HOmeostasis Model Assessment)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seum Total Cholesterol</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum HDL-cholesterol</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Triglycerides</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Uric Acid</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Creatinine</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractional Excretion UA</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine pH</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>One 40 mg tablet once a day for 6 months</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <other_name>Uloric</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 21 years

          -  Gout

          -  Hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women).

        Exclusion Criteria:

          -  Current treatment with insulin, azathioprine, mercaptopurine, or theophylline.

          -  Treatment with febuxostat, allopurinol or other uricosuric agents (including losartan,
             probenecid) within the past year

          -  Uncontrolled hypertension (clinic systolic blood pressure &gt; 160 mmHg or diastolic
             blood pressure &gt; 90 mmHg within the past 6 months)

          -  Uncontrolled diabetes mellitus (HbA1c &gt; 7%)

          -  estimated GFR &lt; 60 ml/min by MDRD

          -  Elevated liver function tests (AST or ALT greater than 3 times the upper limit of
             normal)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naim M Maalouf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8885</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <results_first_submitted>April 2, 2015</results_first_submitted>
  <results_first_submitted_qc>November 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2017</results_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Naim Maalouf</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gout and Hyperuricemia</title>
          <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 2 (2 Months)</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 3 (4 Months)</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Visit 4 (6months)</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gout and Hyperuricemia</title>
          <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BMI</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Uric Acid</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Uric Acid</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Creatinine</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ambulatory Systolic Blood Pressure</title>
        <description>Systolic BP by ambulatory blood pressure monitor.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Ambulatory Systolic Blood Pressure</title>
          <description>Systolic BP by ambulatory blood pressure monitor.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ambulatory Diastolic Blood Pressure</title>
        <description>Diastolic BP by ambulatory blood pressure monitor.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Ambulatory Diastolic Blood Pressure</title>
          <description>Diastolic BP by ambulatory blood pressure monitor.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Glucose</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Insulin</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Insulin</title>
          <units>mU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity Measured by HOMA (HOmeostasis Model Assessment)</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity Measured by HOMA (HOmeostasis Model Assessment)</title>
          <units>Homeostatic model assessment for Insulin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread=".83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seum Total Cholesterol</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Seum Total Cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" spread="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum HDL-cholesterol</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum HDL-cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Triglycerides</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Triglycerides</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" spread="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Uric Acid</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Uric Acid</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208" spread="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine Creatinine</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Creatinine</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1332" spread="669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fractional Excretion UA</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Excretion UA</title>
          <units>mg/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urine pH</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gout and Hyperuricemia</title>
            <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Urine pH</title>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gout and Hyperuricemia</title>
          <description>Adult patients (age &gt; 21 years) with gout and hyperuricemia (serum uric acid &gt; 7.0 mg/dl in men and &gt;6.0 mg/dl in women) requiring uric acid lowering therapy.
Febuxostat: One 40 mg tablet once a day for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Blood</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Liver Function Test</sub_title>
                <description>Serum Liver function tests at months 2, 4 and 6.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naim Maalouf. MD</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>214-648-2954</phone>
      <email>naim.maalouf@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

